With new therapeutic modalities for MM gaining favor, including increased use of quadruplet induction and earlier and more frequent use of CAR-T cells that can cause prolonged pancytopenia, the subject of optimal CD34+ cell dose in auto-HCT for MM has gained renewed interest [12, 13]. This evidence concerns the gene CD34 and Miyoshi myopathy.